S&P Futures
5,896.00 -24.00 (-0.41%) Dow Futures
43,287.00 -253.00 (-0.58%) Nasdaq Futures
20,573.50 -60.00 (-0.29%) Russell 2000 Futures
2,290.60 -27.10 (-1.17%) Crude Oil
68.78 -0.38 (-0.55%) Gold
2,636.40 +21.80 (+0.83%)
IceCure Medical Ltd (ICCM)
After hours:
| Previous Close | 0.6074 |
| Open | 0.6300 |
| Bid | 0.5964 x 300 |
| Ask | 0.6100 x 1200 |
| Day's Range | 0.5900 - 0.6300 |
| 52 Week Range | 0.4800 - 1.5700 |
| Volume | |
| Avg. Volume | 692,671 |
| Market Cap | 33.712M |
| Beta (5Y Monthly) | 2.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2900 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.22 |
Medical Device NetworkIceCure’s cryoablation system for breast cancer treatment gains FDA panel support
Based on the latest recommendation, the company anticipates receiving marketing authorisation for the system in the first quarter of 2025.
PR NewswireFDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced the U.S. Food and Drug Administration's ("FDA") Medical Device Advisory Committee Panel's (the "Advisory Panel") favorable recommendation with 9 panelists voting in favor and 5 voting against the benefit-risk profile of IceCure's ProSense®. The majority of panelists vote
- PR Newswire
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
IceCure Medical Ltd. (NASDAQ: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that a large number of public comments have been posted from key stakeholders ahead of the U.S. Food and Drug Administration (the 'FDA') Medical Device Advisory Committee Panel (the 'Advisory Panel') for marketing authorization of ProSense® cryoablation in early-st
